South korea mammography market size in 2026 is estimated at USD 86.63 million, growing from 2025 value of USD 79.64 million with 2031 projections showing USD 131.94 million, growing at 8.78% CAGR over 2026-2031. This report is Segmented by Product Type (Digital Systems, Analog Systems, Breast Tomosynthesis 3-D, Other Product Types), End User (Hospitals, Specialty Breast Clinics, Diagnostic Imaging Centers), Technology (2-D Digital Mammography, 3-D Digital Breast Tomosynthesis, Others). The Market Forecasts are Provided in Terms of Value (USD).
Legacy 2-D systems continue to serve lower-volume clinics, yet replacement cycles accelerate as DBT becomes the clinical baseline. Corporate procurement teams justify premium equipment by citing 20-65% higher invasive detection rates, especially relevant for the 70% dense-breast prevalence cohort. Digital breast tomosynthesis adoption aligns with national AI strategies, amplifying software subscriptions linked to each installed unit. Vendors now bundle cloud PACS storage and AI-CAD licences, transforming one-time hardware sales into recurring revenue streams.
South Korea Mammography Market Trends and Insights
Rising Incidence of Breast Cancer Among Women
Breast-cancer cases reached 33,335 in 2025, making the disease the most common malignancy among Korean women. Incidence rose 205.26% between 1990 and 2021, far outpacing regional averages. The 5-year relative survival rate climbed to 93.6% for the 2015-2019 cohort, underscoring the screening program’s clinical payoff. Women now delay childbirth and concentrate in urban settings, two established risk correlates. As the 50-59-year cohort expands, demand for mammography units rises, strengthening the South Korea mammography market.Expansion of NCSP Reimbursement for Biennial Screening
NCSP now covers 90% of the cost for biennial mammography among women aged ≥ 40 years, eliminating out-of-pocket fees. Participation improved, recall rates fell from 17.2% in 2009 to 11.2% in 2020, and detection rates grew from 1.5 to 3.1 per 1,000 screens. Rural uptake rose fastest, narrowing historical access gaps. Policymakers are assessing ultrasound reimbursement for dense breasts, which could elevate screening throughput further.Radiation-Dose Concerns Among Women in Their 40s
Average scatter radiation is only 0.87 mGy at the sternum, yet fear persists. Educational campaigns and dose-reduction software seek to reassure patients, but anxiety suppresses screening intent, constraining near-term uptake.Other drivers and restraints analyzed in the detailed report include:
- Rapid Switch-Over to Digital Breast Tomosynthesis Since 2023 Reimbursement
- AI-Powered CAD Improving Detection & Workflow
- Blood-Based Tests Expanding Screening Funnel
- 5G-Enabled Remote QA Networks for Rural Clinics
- Patient Discomfort Shifting Preference to Ultrasound/Blood Tests
Segment Analysis
The South Korea mammography market size for digital equipment led all product categories, holding 61.72% share in 2025. Analog units fade as hospitals modernize electronic medical record (EMR) systems that require digital images. Breast tomosynthesis revenue will grow at a 10.05% CAGR, supported by reimbursement parity and superior cancer-detection metrics. Although capital costs remain steep, workflow gains and lower recall rates shorten return-on-investment periods. Niche categories such as contrast-enhanced mammography gain clinical traction where specificity is paramount. The Ministry of Food and Drug Safety (MFDS) now requires AI integration disclosure under the 2025 Digital Medical Products Act, further tilting demand toward smart digital platforms.Legacy 2-D systems continue to serve lower-volume clinics, yet replacement cycles accelerate as DBT becomes the clinical baseline. Corporate procurement teams justify premium equipment by citing 20-65% higher invasive detection rates, especially relevant for the 70% dense-breast prevalence cohort. Digital breast tomosynthesis adoption aligns with national AI strategies, amplifying software subscriptions linked to each installed unit. Vendors now bundle cloud PACS storage and AI-CAD licences, transforming one-time hardware sales into recurring revenue streams.
Complete Report Scope:
- By Product Type
- Digital Systems
- Analog Systems
- Breast Tomosynthesis (3-D)
- Other Product Types
- By End User
- Hospitals
- Specialty Breast Clinics
- Diagnostic Imaging Centers
- By Technology
- 2-D Digital Mammography
- 3-D Digital Breast Tomosynthesis
- Others
List of Companies Covered in this Report:
- Hologic
- GE Healthcare
- Siemens Healthineers
- Fujifilm Holdings Corp.
- Canon
- Koninklijke Philips
- Carestream Health
- Samsung Group
- Shimadzu
- Agfa-Gevaert
- Planmed
- Neusoft Medical Systems
- Genoray
- Bemems
- Lunit
- Bertis
- iCAD Inc.
- Sectra
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Hologic Inc.
- GE HealthCare
- Siemens Healthineers
- Fujifilm Holdings Corp.
- Canon Medical Systems Corp.
- Koninklijke Philips N.V.
- Carestream Health Inc.
- Samsung Medison
- Shimadzu Corp.
- Agfa-Gevaert Group
- Planmed Oy
- Neusoft Medical Systems
- Genoray Co. Ltd
- Bemems Co. Ltd
- Lunit Inc.
- Bertis
- iCAD Inc.
- Sectra AB
